CA2987697A1 - Derive de xanthine et utilisation comme inhibiteur de dipeptidyl peptidase-4 (dpp4) - Google Patents

Derive de xanthine et utilisation comme inhibiteur de dipeptidyl peptidase-4 (dpp4)

Info

Publication number
CA2987697A1
CA2987697A1 CA2987697A CA2987697A CA2987697A1 CA 2987697 A1 CA2987697 A1 CA 2987697A1 CA 2987697 A CA2987697 A CA 2987697A CA 2987697 A CA2987697 A CA 2987697A CA 2987697 A1 CA2987697 A1 CA 2987697A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acid
solvates
acceptable salts
xanthine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2987697A
Other languages
English (en)
Inventor
Yuzhe GAO
Guocheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Publication of CA2987697A1 publication Critical patent/CA2987697A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur un dérivé de xanthine tel figurant dans la formule I ci-dessous. On détermine R comme suit : choisir R1 à partir du cyanocarbonyle ou du méthoxycarbonyle; choisir R2 à partir d'atomes d'hydrogène ou d'halogène, d'un groupe CI-6 alkyle linéaire ou ramifié substitué ou non à un nombre d'atomes d'halogène entre 1 et 5 ou d'un groupe CI-6 alkoly substitué ou non à un nombre d'atomes d'halogène entre 1 et 5. On détermine X et Y de façon indépendante à partir de C ou de N et la valeur de n est égale à 0, 1, 2, 3, ou 4.
CA2987697A 2015-05-29 2016-05-26 Derive de xanthine et utilisation comme inhibiteur de dipeptidyl peptidase-4 (dpp4) Pending CA2987697A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510290336.0 2015-05-29
CN201510290336 2015-05-29
PCT/CN2016/083406 WO2016192559A1 (fr) 2015-05-29 2016-05-26 Dérivé de la xanthine

Publications (1)

Publication Number Publication Date
CA2987697A1 true CA2987697A1 (fr) 2016-12-08

Family

ID=57440191

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2987697A Pending CA2987697A1 (fr) 2015-05-29 2016-05-26 Derive de xanthine et utilisation comme inhibiteur de dipeptidyl peptidase-4 (dpp4)

Country Status (15)

Country Link
US (1) US10358449B2 (fr)
EP (1) EP3305787B1 (fr)
JP (1) JP6742345B2 (fr)
KR (1) KR20180011270A (fr)
CN (2) CN106188058B (fr)
AU (1) AU2016270100B2 (fr)
CA (1) CA2987697A1 (fr)
ES (1) ES2908658T3 (fr)
HK (1) HK1245796A1 (fr)
IL (1) IL255829B (fr)
MY (1) MY186396A (fr)
RU (1) RU2709348C2 (fr)
SG (1) SG11201709782SA (fr)
TW (1) TWI682931B (fr)
WO (1) WO2016192559A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105983016B (zh) 2015-03-23 2023-08-11 天士力医药集团股份有限公司 一种含有水飞蓟宾的药物组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1496877B1 (fr) * 2002-01-11 2008-10-01 Novo Nordisk A/S Methode et composition permettant de traiter le diabete, l'hypertension, l'insuffisance cardiaque chronique et les troubles de retention de fluide
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP2119717B1 (fr) * 2004-02-18 2018-01-17 Boehringer Ingelheim International GmbH 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que complexe DDP IV
DE102004008112A1 (de) * 2004-02-18 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
CN103172633B (zh) * 2011-12-22 2016-08-03 成都地奥制药集团有限公司 一种化合物及其制备方法和用途

Also Published As

Publication number Publication date
RU2017145919A (ru) 2019-07-02
TW201643166A (zh) 2016-12-16
RU2017145919A3 (fr) 2019-08-09
HK1245796A1 (zh) 2018-08-31
JP2018520120A (ja) 2018-07-26
CN106188058B (zh) 2020-11-06
IL255829B (en) 2021-02-28
MY186396A (en) 2021-07-22
CN107709324A (zh) 2018-02-16
JP6742345B2 (ja) 2020-08-19
EP3305787A4 (fr) 2018-11-21
ES2908658T3 (es) 2022-05-03
EP3305787B1 (fr) 2022-02-16
SG11201709782SA (en) 2017-12-28
WO2016192559A1 (fr) 2016-12-08
AU2016270100A1 (en) 2017-12-14
RU2709348C2 (ru) 2019-12-18
US10358449B2 (en) 2019-07-23
US20180162860A1 (en) 2018-06-14
AU2016270100B2 (en) 2020-02-13
IL255829A (en) 2018-01-31
KR20180011270A (ko) 2018-01-31
TWI682931B (zh) 2020-01-21
CN106188058A (zh) 2016-12-07
EP3305787A1 (fr) 2018-04-11
CN107709324B (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
EP2010505B1 (fr) Composés hétérocycliques et leurs utilisations dans le traitement de troubles sexuels
EP3104706B1 (fr) Compositions et procédés les utilisant pour le traitement de maladie neurodégénérative et mitochondriale
EP2786998B1 (fr) Composés de thiényl [3, 2-d]pyrimidin-4-one, procédé de préparation, compositions pharmaceutiques et utilisation associés
US10155775B2 (en) Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors
EP3470409A1 (fr) Composes dérivés de benzotriazole a et b amide non satures utilises comme inhibiteurs de tgf-br1
KR20080007443A (ko) ｃ-ＭＥＴ 자기 인산화 저해 작용을 갖는 티에노피리딘유도체, 퀴놀린 유도체, 및 퀴나졸린 유도체
EP3661935B1 (fr) Pyrazolopyrimidines substituées pouvant être employées en tant qu'inhibiteurs de kinases
JP7404616B2 (ja) ホスホジエステラーゼ阻害剤の使用
EP3214079A1 (fr) Dérivés benzo à cycle à six chaînons en tant qu'inhibiteur de la dpp-4 et son utilisation
US20200223851A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
US11912663B2 (en) Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses
US20130345243A1 (en) 1h-pyrollo[3,2-d]pyrimidinedione derivatives
CA3143196A1 (fr) Inhibiteurs de l'acetyl-coa synthetase 2 (acss2) et leurs procedes d'utilisation
AU2016270100B2 (en) Xanthine derivative
CN102977091B (zh) 芳香烷酰基四氢-β-咔啉及其衍生物在治疗代谢性疾病中的应用
CN110229150B (zh) 咪唑并[4,5-c]吡啶类衍生物及其用途
TW202228696A (zh) 稠合雜環類化合物及其製備方法和醫藥用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119

EEER Examination request

Effective date: 20210119